The stock of Dexcom Inc (NASDAQ: DXCM) has increased by 2.22 when compared to last closing price of 88.78.Despite this, the company has seen a gain of 1.89% in its stock price over the last five trading days. youtube.com reported 2025-02-21 that Friday’s trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an “umbrella’ to protect their portfolios.
Is It Worth Investing in Dexcom Inc (NASDAQ: DXCM) Right Now?
Dexcom Inc (NASDAQ: DXCM) has a price-to-earnings ratio of 63.70x that is above its average ratio. Additionally, the 36-month beta value for DXCM is 1.29. There are mixed opinions on the stock, with 17 analysts rating it as a “buy,” 5 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for DXCM is 385.48M and currently, short sellers hold a 2.55% ratio of that float. The average trading volume of DXCM on February 25, 2025 was 3.50M shares.
DXCM’s Market Performance
DXCM stock saw an increase of 1.89% in the past week, with a monthly gain of 3.48% and a quarterly increase of 21.19%. The volatility ratio for the week is 2.89%, and the volatility levels for the last 30 days are 2.52% for Dexcom Inc (DXCM). The simple moving average for the past 20 days is 3.29% for DXCM’s stock, with a 3.89% simple moving average for the past 200 days.
Analysts’ Opinion of DXCM
Many brokerage firms have already submitted their reports for DXCM stocks, with Redburn Atlantic repeating the rating for DXCM by listing it as a “Buy.” The predicted price for DXCM in the upcoming period, according to Redburn Atlantic is $115 based on the research report published on February 03, 2025 of the current year 2025.
Robert W. Baird, on the other hand, stated in their research note that they expect to see DXCM reach a price target of $104, previously predicting the price at $86. The rating they have provided for DXCM stocks is “Outperform” according to the report published on January 16th, 2025.
Robert W. Baird gave a rating of “Neutral” to DXCM, setting the target price at $80 in the report published on July 26th of the previous year.
DXCM Trading at 8.81% from the 50-Day Moving Average
After a stumble in the market that brought DXCM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.09% of loss for the given period.
Volatility was left at 2.52%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +2.25% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.74% upper at present.
During the last 5 trading sessions, DXCM rose by +1.89%, which changed the moving average for the period of 200-days by -30.00% in comparison to the 20-day moving average, which settled at $87.86. In addition, Dexcom Inc saw 16.69% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DXCM starting from Sylvain Jereme M, who sale 2,090 shares at the price of $86.91 back on Jan 29 ’25. After this action, Sylvain Jereme M now owns 83,526 shares of Dexcom Inc, valued at $181,650 using the latest closing price.
Dolan Matthew Vincent, the EVP, Strategy & Corporate Dev of Dexcom Inc, sale 1,183 shares at $86.91 during a trade that took place back on Jan 29 ’25, which means that Dolan Matthew Vincent is holding 42,044 shares at $102,820 based on the most recent closing price.
Stock Fundamentals for DXCM
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.6 for the gross margin
The net margin for Dexcom Inc stands at 0.14. The total capital return value is set at 0.17. Equity return is now at value 27.63, with 9.04 for asset returns.
Based on Dexcom Inc (DXCM), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 31.58.
Currently, EBITDA for the company is 840.7 million with net debt to EBITDA at 2.1. When we switch over and look at the enterprise to sales, we see a ratio of 9.27. The receivables turnover for the company is 4.01for trailing twelve months and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In conclusion, Dexcom Inc (DXCM) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
